3CLpro Multi-Site Combination for Dimerization Blocking in SARS-CoV-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for COVID-19, such as repurposed FDA drugs, are inadequate in effectively inhibiting the SARS-CoV2 3C-like main protease (3CLpro), which is enzymatically active only in its dimeric form, necessitating a therapeutic strategy to target protein-protein interfaces to prevent monomer interaction.
Innovation Solution
A pharmaceutical combination of two agents, one targeting an orthosteric site and another targeting an allosteric or interface site of the 3CLpro complex, to inhibit dimerization and enhance therapeutic efficacy while reducing dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If repurposed FDA drugs are used to treat COVID-19, then treatment availability is improved, but antiviral efficacy is insufficient
Solution Approach 1:
The patent combines multiple drugs with different mechanisms of action (e.g., remdesivir, lopinavir, ritonavir, hydroxychloroquine) into a single pharmaceutical composition. This merging approach allows the composition to simultaneously inhibit viral replication through multiple pathways, thereby improving antiviral efficacy while maintaining the advantage of using already-approved drugs for rapid availability.
2Reliability
If higher dosage of single drug is administered to improve therapeutic effect, then antiviral efficacy is improved, but toxicity increases
Solution Approach 1:
The patent divides the therapeutic effect into multiple components achieved by different drugs in the composition. Instead of relying on a single high-dose drug, the composition uses multiple drugs at optimized individual doses to collectively achieve the desired therapeutic effect. This segmentation allows each drug to contribute partially to the overall effect, reducing the toxicity associated with high doses of any single agent.
3Reliability
If protein-protein interface is targeted to prevent dimerization, then enzymatic activity inhibition is improved, but drug design complexity increases
Solution Approach 1:
The patent uses computational methods (molecular dynamics simulations, docking studies) as intermediaries to identify and characterize the dimerization interface of 3CLpro. These computational tools serve as mediators between the biological target (protein-protein interface) and the drug design process, enabling the identification of critical residues and binding pockets without requiring complex experimental structural biology for every screening step.
Data Source
AI summary
Provided is a method for treating a SARS-CoV2 3CLpro-related disease in a subject in need thereof by blocking dimerization of 3C-like main protease (3CLpro) of the SARS-CoV2, including administering to the subject a first agent which binds to a first binding site of a SARS-CoV2 3CLpro complex and a second agent which binds to a second binding site of the SARS-CoV2 3CLpro complex, wherein the first binding site and the second binding site are functionally different sites in the three-dimensional structure of the SARS-CoV2 3CLpro complex. Also provided is a pharmaceutical combination including the first agent and the second agent for suppressing SARS-CoV2, thereby alleviating COVID-19.